Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023. - Barron's

As reported by Barron's

Novartis pauses clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Barron's ↗

Market Samachar is a news aggregator. This article was originally published by Barron's. Tap the button above to read the full story on their site.

INDIAN Amid orders flowing in, Hitachi emerges as a potential 'buy' option for investors Markets-Economic Times
COMPANIES Happiest Minds shares fall for 5th day as merger concerns weigh Stocks-Markets-Economic Times
INDIAN India's banking system liquidity surplus hits over 4.5-year high at Rs 7.76 lakh crore Markets-Economic Times
INDIAN Rupee holds firm at 94.97 on RBI dollar sales Markets-Economic Times
COMPANIES D-Street poised for a positive start as GIFT Nifty trades firmly higher Stocks-Markets-Economic Times
GLOBAL Trump $1 coin makes him first president on US currency in a century BBC News
INDIAN Market rout brings dividend stocks in limelight: Time to switch? Share Market Today
INDIAN Asian markets today: Nikkei 225, Kospi rise marginally amid US-Iran war uncertainty mint - markets

Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023. - Barron's

More from Market Samachar